ARWR: Arrowhead Pharmaceuticals Inc P/S Multiple

Corporate company logo of Arrowhead Corp (ARWR)

Regulatory pressure and potential failures in final RNA drug trials pose serious threats to Arrowhead Pharmaceuticals (ARWR). A lack of sales coupled with massive research expenditures increases dependence on partners. The price-to-sales ratio visualizes these risks, where the value 9.90 describes the current market valuation. Leading geneticists, retained through lucrative options and grants, ensure the stability of development.

ARWR: arrowheadpharma.com Price-to-Revenue Ratio 07/04/2022 - 11/13/2026

Arrowhead Pharmaceuticals Inc (ARWR) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart arrowheadpharma.com|ARWR - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Arrowhead Pharmaceuticals Inc|ARWR - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Arrowhead Pharmaceuticals|ARWR - Company Book Value|Market Value to Book Value arrowheadpharma.com|ARWR - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Arrowhead Pharmaceuticals|ARWR - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Arrowhead Corp|ARWR - Company Aggregate Debts|Debt to Net Assets Ratio Arrowhead Pharmaceuticals Inc|ARWR - Company Long-Term Debts|Short-Term Debt Arrowhead Pharmaceuticals|Quick Ratio arrowheadpharma.com
- earnings and valuation multiples information:
ARWR - Net Profit|Net Profit Forecast Arrowhead Pharmaceuticals|ARWR - Price to Earnings Ratio|Future Price to Earnings Multiple Arrowhead Pharma|ARWR - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Arrowhead Pharmaceuticals Inc|ARWR - Operating profit EBITDA|Earnings per share for the trailing year Arrowhead Pharmaceuticals|ARWR - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth arrowheadpharma.com|ARWR - Earnings per share growth in current year|Expected earnings per share trend next year Arrowhead Pharmaceuticals
- total revenue and sales volume data:
ARWR - Company Revenue|Company Future Sales Volume arrowheadpharma.com|ARWR - P/S Multiple|Forward P/S Multiple Arrowhead Pharmaceuticals Inc
General company analysis:arrowheadpharma.com, ARWR
Mass-produced product of Arrowhead Pharmaceuticals

To objectively screen issuer reliability, the P/S ratio is utilized to compare market capitalization against annual revenue, enabling the determination of the value of each unit of sales while disregarding the volatility of quarterly reports. The price-to-sales multiple history for Arrowhead Pharmaceuticals (ARWR) reflects market expectations for the monetization of RNA therapeutics, where stable demand for liver disease treatments serves as the foundation for assessing the business's fair value.

Competing companies

MIRM (mirumpharma.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple DVAX (Dynavax Technologies Corp)|P/S Multiple Arbutus Biopharma Corp ABUS|IVA - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio GYRE (Gyre Therapeutics Corp.)|Assembly Biosciences (ASMB) - Price-to-Revenue Ratio|Galectin Therapeutics Inc. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Genfit SA|Price to Sales DURECT Corp. DRRX|Market Cap to Revenue ALGS (Aligos Therapeutics)|Market Cap to Revenue biovieinc.com BIVI|P/S Multiple GLMD (Galmed Pharmaceuticals Ltd.)|Market Capitalization-to-Revenue Ratio NDRA|Hepion Pharma - P/S Multiple